Tryptamine Therapeutics ( (AU:TYP) ) just unveiled an update.
Tryptamine Therapeutics has signed an agreement with Swinburne University to conduct a world-first clinical trial assessing the safety and efficacy of TRP-8803, an IV-infused psilocin formulation, for treating Binge Eating Disorder (BED). This trial, which follows promising results from a previous study using oral psilocybin, aims to address the lack of approved treatments for BED, a prevalent eating disorder in the US and Australia. The trial will involve 12 patients and is expected to provide insights that could enhance the company’s clinical development and regulatory strategies for TRP-8803, potentially impacting the treatment landscape for BED and other neuropsychiatric conditions.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited, also known as Tryp, is a clinical-stage biopharmaceutical company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Their lead asset, TRP-8803, is a proprietary, scalable, and innovative formulation of IV-infused psilocin.
YTD Price Performance: -27.50%
Average Trading Volume: 1,638,592
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$44.61M
See more insights into TYP stock on TipRanks’ Stock Analysis page.